MALT1

Exscientia Business and Financial Update for the Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Federal Reserve Bank, Automation, Ovarian cancer, DSM-IV codes, CDK7, Learning, LSD1, Bill, Half-life, UGT1A1, International, Inflammation, Patient, EDT, G&A, Cancer, AI, Bristol Myers Squibb, IND, Medicine, Merck Group, Sumitomo Pharma, PKC, ID, GMT, MALT1, Acute leukemia, Pharmaceutical industry

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.
  • Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT.
  • This study has the potential to support the ongoing development of ‘539, Exscientia’s LSD1 inhibitor
    In July 2023, Exscientia launched EXCYTE-1, a first-of-its-kind prospective observational study in ovarian cancer.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .

Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting

Retrieved on: 
Wednesday, March 20, 2024
Health, Technology, Health Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Safety, ACS, Pharmacokinetics, BTK, Therapy, MALT1, Lymphoid leukemia, American Chemical Society, Pharmaceutical industry

Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.
  • The oral presentation provided an overview of how Schrödinger leveraged its computational approaches at scale to discover SGR-1505.
  • Reaching a development candidate can take three to six years and typically involves synthesizing up to 5,000 molecules per program.
  • Schrödinger recently completed a Phase 1 study showing that SGR-1505 was well tolerated in a Phase 1 study of 73 healthy volunteers.

Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Apps, Applications, Technology, Medical Devices, Other Technology, Health Technology, Software, Biotechnology, Health, Pharmaceutical, AML, G protein-coupled receptor, ASH, Investment, FEP, CDC7, Growth, Table, AbbVie, NLRP3, MALT1, Society, GAAP, Myelodysplastic syndrome, GPCR, Lymphoid leukemia, Solubility, Patient, Drug discovery, HERG, Acute myeloid leukemia, MBBS, IND, Research, Pharmaceutical industry

Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Key Points: 
  • Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.
  • For the first quarter of 2024, software revenue is expected to range from $33 million to $35 million.
  • “We had a very strong year in 2023, with significant growth in our software and drug discovery revenue and substantial progress in our proprietary pipeline and at our co-founded companies.
  • Schrödinger will host a conference call to discuss its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, at 4:30 p.m.

Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals

Retrieved on: 
Monday, January 8, 2024
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, PKA, Lilly, Drug discovery, Lymphoid leukemia, ADMET, IND, CDC7, MDS, Eli Lilly and Company, MBBS, NLRP3, MALT1, Webcast, Patient, Therapy, AML, Pharmaceutical industry

Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.

Key Points: 
  • Schrödinger , Inc. (Nasdaq: SDGR), Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today provided an update on its progress across the business and announced its development and operational goals for 2024.
  • Today Schrödinger announced an expanded, three-year, software agreement with Eli Lilly and Company.
  • The three-year agreement builds on the collaboration established in 2022.
  • Schrödinger will provide advanced support to ensure full integration and optimization of the platform across Lilly’s research sites.

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

Retrieved on: 
Thursday, December 14, 2023
Software, Research, General Health, Pharmaceutical, Medical Devices, Technology, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, CNS, Safety, CDC7, Bone marrow, Lymphoid leukemia, Acute myeloid leukemia, ASH, IND, Syndrome, Pipeline, Brain, Patient, Neurology, Lung cancer, PRMT5, Neoplasm, Therapy, Oregon Health Plan, Toxic encephalopathy, MALT1, AML, NLRP3, Society, Myelodysplastic syndrome, EGFR, Outline, Pharmaceutical industry, Vaccine

The data support continued evaluation of SGR-1505 in the ongoing Phase 1 study in patients with relapsed or refractory B-cell malignancies.

Key Points: 
  • The data support continued evaluation of SGR-1505 in the ongoing Phase 1 study in patients with relapsed or refractory B-cell malignancies.
  • “These data add significantly to our understanding of SGR-1505 and inform our clinical development strategy in hematologic malignancies.
  • Schrödinger is presenting three new proprietary discovery programs at Pipeline Day, targeting EGFRC797S, PRMT5-MTA and NLRP3.
  • Schrödinger is advancing multiple oncology programs designed to exploit the intrinsic vulnerabilities of cancer cells through synthetic lethality and inhibition of DNA-damage repair.

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, Technology, Health Technology, Software, Pharmaceutical, Biotechnology, Webcast, Cytokine, Decitabine, Safety, CDC7, Lymphoid leukemia, ASH, Acute myeloid leukemia, Harmonic pitch class profiles, B-cell lymphoma, Patient, Abstract, NF, Pharmacokinetics, Therapy, Venetoclax, Chronic lymphocytic leukemia, Significance, Trial of the century, Human, MALT1, AML, Potent, Cancer, Society, Myelodysplastic syndrome, NHL, CLL, Pharmaceutical industry, Vaccine

The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.

Key Points: 
  • The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.
  • The company will report additional data from the healthy subject study at its Pipeline Day on December 14, 2023.
  • “The pharmacological data for SGR-1505 and SGR-2921 demonstrate that our development candidates have favorable, differentiated profiles with best-in-class potential,” stated Karen Akinsanya, Ph.D., president of R&D therapeutics at Schrödinger.
  • “Our progress within these programs further validates our computational approach to designing therapies with the potential to address the limitations of current treatments.

Exscientia Business Update for Third Quarter 2023

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Drug design, GBP, NSCLC, IND, MALT1, ESMO, Ovarian cancer, International, GMT, EST, Congress, Head, European Society for Medical Oncology, G&A, PKC, Colorectal cancer, Acute leukemia, Acquisition, Federal Reserve Bank, BMS, Growth, CDK7, ID, Risk, Bristol Myers Squibb, Jaundice, Merck Group, Pancreatic cancer, AlphaFold, Sumitomo Pharma, Lung cancer, LSD1, USD, AI, Berlin, Patient, Toxicity, AML, Automation, Pharmaceutical industry, Medical imaging, Rare-earth element, Fine chemical, Cryptocurrency, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.
  • Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .
  • The increase in revenue quarter over quarter was primarily due to $8.38 million in revenue recognised from the projects that Exscientia and BMS mutually determined not to proceed with further development of under the BMS collaboration.

Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Health Technology, Pharmaceutical, Health, Acute myeloid leukemia, MALT1, Therapy, Myelodysplastic syndrome, Society, ASH, Pharmacokinetics, CDC7, Webcast, Safety, Lymphoid leukemia, Patient, AML, DNA, Pharmaceutical industry

The data support continued development of SGR-1505 as a potential therapy for patients with advanced B-cell malignancies, and a Phase 1 dose-escalation study in this patient population is ongoing.

Key Points: 
  • The data support continued development of SGR-1505 as a potential therapy for patients with advanced B-cell malignancies, and a Phase 1 dose-escalation study in this patient population is ongoing.
  • Additionally, data will be presented for SGR-2921 demonstrating strong anti-leukemic activity in preclinical models of acute myeloid leukemia (AML) representing difficult-to-treat disease.
  • The live presentation can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days.
  • It is recommended that participants register at least 15 minutes in advance of the event.

Schrödinger Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Software, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Technology, Clinical Trials, United European Gastroenterology, PH, PRMT5, Trial of the century, Global health, IND, Acute myeloid leukemia, MALT1, Food, PKA, FEP, Myelodysplastic syndrome, Regulation of tobacco by the U.S. Food and Drug Administration, GAAP, Mantle cell lymphoma, Research, Bill, Ulcerative colitis, Bill & Melinda Gates Foundation, Pharmacokinetics, CDC7, Phases of clinical research, Webcast, ADMET, UEG, Safety, Overweight, Therapy, Investment, Table, Patient, Cryptocurrency, Pharmaceutical industry, Bank, EU

Schrödinger today updated its financial guidance for 2023.

Key Points: 
  • Schrödinger today updated its financial guidance for 2023.
  • The Phase 1 dose-escalation study in healthy volunteers is nearing completion, and the company expects to report data from the study in the fourth quarter of 2023.
  • Schrödinger will host a conference call to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 4:30 p.m.
  • Schrödinger will host its Pipeline Day in New York City on Thursday, December 14, 2023, beginning at 10:00 a.m.

HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
CBM, NF-κB, Non-Hodgkin lymphoma, IND, Biotechnology, Drug resistance, Multiple myeloma, Hotspot, Cell, Protein, Society, ASH, Lymphoid neoplasms with plasmablastic differentiation, Pharmacology, Bone marrow, Therapy, Manchester Grand Hyatt Hotel, Pharmaceutical industry, MALT1, Lymphoma

BOSTON, Nov. 2, 2023 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced it will present preclinical data from the Company's highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program in an oral presentation at the 2023 American Society of Hemotology (ASH) Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.

Key Points: 
  • MALT1 is a component of the CARD11-BCL10-MALT1 (CBM) protein complex, which serves as a key regulator of NFkB signaling in cells, including B and T cells.
  • MALT1 is implicated in a range of hematological malignancies, including Non-Hodgkin's lymphoma, as well as other lymphomas and selected solid tumors.
  • Leveraging our proprietary Smart Allostery™ platform, HotSpot has developed first-in-class small molecules designed to selectively inhibit the scaffolding function of MALT1, a dominant driver of the NFkB pathway.
  • This oral presentation will describe the differentiated preclinical profile for HotSpot's scaffolding inhibitor, including the potential for an improved efficacy and safety profile versus traditional MALT1 inhibitors that target protease function.